Skip to main content

Cristina Hernández Pascual

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Cristina Hernández Pascual

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) Grant Agreement nº 278040

IP: Rafael Simó Canonge
Collaborators: Cristina Hernández Pascual
Funding agency: EUROPEAN COMMISSION
Funding: 936725.31
Reference: EUROCONDOR_FP7HEALTH2011/VHIR
Duration: 01/03/2012 - 30/06/2016

Neurodegeneration as an early event in the pathogenesis of diabetic netinopathy. Study of involved mechanisms and new therapeutic strategies

IP: Rafael Simó Canonge
Collaborators: Cristina Hernández Pascual, Patricia Bogdanov Baruj
Funding agency: European Foundation for the Study of Diabetes
Funding: 100000
Reference: EFSD-2010-02
Duration: 28/10/2010 - 27/04/2012

Grup de Recerca en Diabetis i Metabolisme

IP: Rafael Simó Canonge
Collaborators: Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Andreea Ciudin Mihai
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 43680
Reference: 2009 SGR 739
Duration: 01/01/2010 - 30/04/2014

Sex hormone-binding globulin (SHBG): Identification of the molecular mechanisms that regulate its expression and role in body fat distribution and in the development of type 2 diabetes

IP: David Martinez Selva
Collaborators: Rafael Simó Canonge, Cristina Hernández Pascual
Funding agency: Instituto de Salud Carlos III
Funding: 42000
Reference: CP08/00058
Duration: 01/01/2009 - 31/12/2011

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Alicia Barberan Masegosa

Alicia Barberan Masegosa

Research technician
Microbiology
Read more
Immaculada Pérez Gladiador

Immaculada Pérez Gladiador

Administratiu/va. Nivell 5.1
Clinical Research Development Directorate
Read more
Manuel Gomez Duque

Manuel Gomez Duque

Growth and Development
Read more
Mª Angeles Linde Sillo

Mª Angeles Linde Sillo

Research technician
Growth and Development
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.